<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fluorouracil (topical): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fluorouracil (topical): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fluorouracil (topical): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11685" href="/d/html/11685.html" rel="external">see "Fluorouracil (topical): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8100790"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Carac;</li>
<li>Efudex;</li>
<li>Fluoroplex [DSC];</li>
<li>Tolak</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869168"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Efudex;</li>
<li>Tolak</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F8100817"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Antimetabolite;</li>
<li>
                        Antineoplastic Agent, Antimetabolite (Pyrimidine Analog);</li>
<li>
                        Topical Skin Product</li></ul></div>
<div class="block doa drugH1Div" id="F8100901"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Fluoroplex 1% has been discontinued in the United States for &gt;1 year.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="400349fd-64b5-47e7-828f-e76462d204f6">Actinic or solar keratosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Actinic or solar keratosis:</b>
<b>Topical:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Cream (0.5%): Apply thin film to lesions once daily for up to 4 weeks, as tolerated.</p>
<p style="text-indent:-2em;margin-left:4em;">Cream (1%): Apply to lesions twice daily for 2 to 6 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">Cream (4%): Apply to lesions once daily for 4 weeks as tolerated.</p>
<p style="text-indent:-2em;margin-left:4em;">Cream (5%) or solution (2% and 5%): Apply to lesions twice daily for 2 to 4 weeks (apply until inflammatory response reaches erosion stage, then stop); complete healing may not be evident for 1 to 2 months following treatment.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="87966864-94b9-43e8-8609-89f9f255dc09">Basal cell carcinoma, superficial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Basal cell carcinoma, superficial: Topical:</b> Cream (5%) or solution (5%): Apply to affected lesions twice daily for 3 to 6 weeks; treatment may be continued for up to 10 to 12 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e9a7917d-4b75-4515-a406-58be6baad5be">Penile carcinoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Penile carcinoma (in situ) (off-label use; based on limited data): Topical: </b>Cream (5%): Apply to lesion for 12 hours every 48 hours for 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22421082']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22421082'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bbbad05d-ba55-479d-af49-f4352d14c9d1">Squamous cell carcinoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Squamous cell carcinoma (in situ; Bowen disease) (off-label use; based on limited data): Topical: </b>Cream (5%): Apply to lesion(s) twice daily for 9 weeks; a repeat course may be applied for recurrences (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12447619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12447619'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991681"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988996"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F8100902"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F8100846"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dermatologic: Application site scaling (≤95%), application site dryness (70% to ≤95%), stinging of the skin (application site: ≤87%), skin erosion (application site: 25% to 68%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Local: Application site erythema (90% to 99%), application site reaction (92% to 97%; crusting: 87%), application site burning (60% to ≤87%), application site pruritus (85%), application site edema (14% to 69%), application site pain (31% to 61%)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Central nervous system: Headache (4%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dermatologic: Skin irritation (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Infection: Common cold (5%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ophthalmic: Eye irritation (3% to 7%; burning, watering, sensitivity, stinging, itching)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Respiratory: Sinusitis (5%)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&lt;1%, postmarketing, and/or case reports: Allergic contact dermatitis, alopecia, anxiety, bullous pemphigoid, burning sensation of skin, conjunctival irritation, conjunctivitis, corneal disease, eosinophilia, eye irritation, herpes simplex infection, hyperpigmentation, ichthyosis, inflammation, insomnia, irritability, lacrimation, leukocytosis, lymphocytic leukemia, medicine-like taste, muscle tenderness, nasal discomfort, pain, pancytopenia, pruritus, scarring, skin blister, skin irritation, skin neoplasm (nonmelanoma), skin photosensitivity, skin rash, skin tenderness, stomatitis, suppuration, swelling, swelling of eye, telangiectasia, thrombocytopenia, toxic granulations, ulcer, urticaria</p></div>
<div class="block coi drugH1Div" id="F8100843"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to fluorouracil or any component of the formulation; dihydropyrimidine dehydrogenase (DPD) enzyme deficiency; patients who are or may become pregnant.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Concurrent use with brivudine, sorivudine, and analogues; breastfeeding.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F8100844"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Delayed-type hypersensitivity reactions, including allergic contact dermatitis, have been reported. Severe pruritus or eczema (at the application site or at a distant site) may be indicative of hypersensitivity. Patch testing may not be useful in the evaluation of these reactions. Discontinue immediately for signs of hypersensitivity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Local skin reactions: When applied to a lesion, erythema followed by vesiculation, desquamation, erosion and reepithelialization occurs. Local reactions and alterations in skin appearance may persist for several weeks after discontinuation. Bruising, burning, crusting, dryness, edema, irritation, pain, pruritus, scaling, scarring, soreness, stinging, and ulceration may commonly result from topical therapy. Increased absorption through ulcerated or inflamed skin is possible.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular adverse reactions: Corneal and conjunctival disorders have occurred with topical fluorouracil; avoid application to the periocular area.</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: Topical fluorouracil is associated with photosensitivity, including severe sunburn. Avoid prolonged exposure to sunlight or UV irradiation during treatment; reaction intensity may be increased.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dihydropyrimidine dehydrogenase enzyme deficiency: Dihydropyrimidine dehydrogenase (DPD) enzyme deficiency may result in increased cytotoxic activity and severe toxicity with topical fluorouracil. Life-threatening systemic toxicity has been reported with topical fluorouracil in a patient with DPD enzyme deficiency; signs/symptoms included bloody diarrhea, stomatitis, esophagus, stomach, and small bowel inflammation, severe abdominal pain, vomiting, chills, fever, erythematous skin rash, neutropenia, and thrombocytopenia. Discontinue if signs of DPD deficiency develop.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP 1997; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peanut oil: Some dosage forms contain peanut oil.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Avoid application to mucous membranes due to potential for local inflammation and ulceration. Occlusive dressings may increase the severity of inflammation in nearby skin areas (a porous gauze dressing may be applied for cosmetic reasons without increase in reaction). Avoid eyelids, eyes, and periocular area when applying. Wash hands well following application; if ocular exposure occurs, flush with large amounts of water.</p>
<p style="text-indent:-2em;margin-left:4em;">• Household pet safety: Avoid allowing house pets to come into contact with human skin following topical fluorouracil application. Small amounts of fluorouracil ingested by cats or dogs may result in toxic hyperammonemia and high rates of mortality (ISMP [Smetzer 2020]).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878737"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP, 1997; Shehab, 2009).</p></div>
<div class="block prod-avail drugH1Div" id="F57903338"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Fluoroplex 1% has been discontinued in the United States for &gt;1 year.</p></div>
<div class="block foc drugH1Div" id="F8100940"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Carac: 0.5% (30 g) [contains methylparaben, polysorbate 80, propylene glycol, propylparaben, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Efudex: 5% (40 g) [contains methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fluoroplex: 1% (30 g [DSC]) [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tolak: 4% (40 g) [contains cetyl alcohol, methylparaben, peanut oil, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5% (30 g); 5% (40 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2% (10 mL); 5% (10 mL)</p></div>
<div class="block geq drugH1Div" id="F8100815"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F8100942"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Carac External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per gram): $99.91</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Efudex External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per gram): $1.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Fluorouracil External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per gram): $59.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per gram): $6.43 - $9.62</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Tolak External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per gram): $1.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Fluorouracil External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per mL): $7.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per mL): $11.13</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869169"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Efudex: 5% (40 g) [contains methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tolak: 4% (40 g) [contains cetyl alcohol, methylparaben, peanut oil, propylparaben]</p></div>
<div class="block adm drugH1Div" id="F8100928"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Topical: Apply 10 minutes after washing, rinsing, and drying the affected area. Apply a sufficient amount to cover lesions, preferably using a nonmetal applicator or suitable glove.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream (4%): Apply after washing, rinsing, and drying the affected area. Apply a sufficient amount to cover lesions of the face, ears, and/or scalp with a thin film, using fingertips to gently massage uniformly into skin. </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">If applied with fingertip, wash hands immediately after application. Do not cover area with an occlusive dressing. Topical preparations are for external use only; not for ophthalmic, oral, mucous membrane, or intravaginal use. </p></div>
<div class="block hazard drugH1Div" id="F49132564"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F8100838"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Actinic or solar keratosis:</b> Management of multiple actinic or solar keratoses</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Basal cell carcinoma, superficial  (5%):</b> Treatment of superficial basal cell carcinoma when conventional methods are impractical (eg, due to multiple lesions or difficult treatment sites)</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Establish diagnosis of superficial basal cell carcinoma prior to treatment (has not been proven effective in other types of basal cell carcinomas); surgery is preferred with isolated, easily accessible basal cell carcinomas because success with such lesions is almost 100% and the success rate with fluorouracil cream and solution is ~93%.</p></div>
<div class="block off-label drugH1Div" id="F55013492"><span class="drugH1">Use: Off-Label: Adult</span><p>Penile carcinoma (in situ); Squamous cell carcinoma (in situ; Bowen disease)</p></div>
<div class="block mst drugH1Div" id="F8100787"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Fluorouracil may be confused with flucytosine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:2em;">Curac may be confused with Kuric brand name for methyldopa (NG)</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F9844111"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F8100864"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Fluorouracil (Topical).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49306602"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Use is contraindicated in patients who may become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Females of reproductive potential should use effective contraception during treatment and for 1 month after the final application of topical fluorouracil.</p></div>
<div class="block pri drugH1Div" id="F8100840"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Use is contraindicated in patients who are pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Adverse effects, including ventricular septal defect and miscarriage, have been reported following topical application of fluorouracil products to mucous membranes in pregnant patients.</p></div>
<div class="block brc drugH1Div" id="F20688339"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if fluorouracil (topical) is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, a decision should be made to discontinue breastfeeding or the drug, considering the importance of treatment to the mother.</p></div>
<div class="block pha drugH1Div" id="F8100874"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Fluorouracil is a pyrimidine antimetabolite that interferes with DNA synthesis by blocking the methylation of deoxyuridylic acid to thymidylic acid; blocks DNA synthesis to prevent cell proliferation of fast growing cells and cause cell death.</p></div>
<div class="block phk drugH1Div" id="F9771398"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: ~6% of a topical dose is absorbed systemically (5% cream) </p>
<p style="text-indent:-2em;margin-left:2em;">Time to Peak: ~1 hour following application (4% cream)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961975"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Efudix</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Acler</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Fluoro uracil | Tolak</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Efudix | Fluoroplex | Fluorouracil pc | Tolak</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Efurix | Fluoro uracil</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Efudix</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">5 fluorouracil | 5-fluorouracilo</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Tolak</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Efudix</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Fluorouracilo</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Efudix</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Ezadex</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Fluorouracilo sandoz | Tolak</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Efudix | Tolak</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Efudix</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Efudix | Tolak</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Efudix</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Flonida | Fluo</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Tolerak</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Efudix</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Efudix</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Efudix | Efudix lps | Fuloxitril</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Flonida</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Efudix</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Efudix | Efudix unimedic | Tolak</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Efudix</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Efudix</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Carac | Efudex | Fluoroplex | Tolak</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Efudix</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Tolak</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Efudix</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Efudix</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USPNF.1">
<a name="USPNF.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-topical-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-topical-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22421082">
<a name="22421082"></a>Alnajjar HM, Lam W, Bolgeri M, Rees RW, Perry MJ, Watkin NA. Treatment of carcinoma in situ of the glans penis with topical chemotherapy agents. <i>Eur Urol</i>. 2012;62(5):923-928. doi:10.1016/j.eururo.2012.02.052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-topical-drug-information/abstract-text/22421082/pubmed" id="22421082" target="_blank">22421082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12447619">
<a name="12447619"></a>Bargman H, Hochman J. Topical treatment of Bowen's disease with 5-Fluorouracil. <i>J Cutan Med Surg</i>. 2003;7(2):101-105. doi:10.1007/s10227-002-0158-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-topical-drug-information/abstract-text/12447619/pubmed" id="12447619" target="_blank">12447619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Carac.1">
<a name="Carac.1"></a>Carac (fluorouracil 0.5% cream) [prescribing information]. Bridgewater, NJ: Bausch Health US LLC; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-topical-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-topical-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-EfudexCan.1">
<a name="EfudexCan.1"></a>Efudex (fluorouracil) [product monograph]. Laval, Quebec, Canada: Bausch Health Canada Inc; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Efudex.1">
<a name="Efudex.1"></a>Efudex solutions and cream (fluorouracil) [prescribing information]. Sugar Land, TX: Mylan Institutional Inc; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fluoroplex.1">
<a name="Fluoroplex.1"></a>Fluoroplex (fluorouracil topical 1% cream) [prescribing information]. Exton, PA: Almirall LLC; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Valeant.1">
<a name="Valeant.1"></a>Fluorouracil cream (0.5%) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; October 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylan.1">
<a name="Mylan.1"></a>Fluorouracil topical cream (5%) [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals; January 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Solubiomix.1">
<a name="Solubiomix.1"></a>Fluorouracil topical solution (2% and 5%) [prescribing information]. Madisonville, LA: Solubiomix LLC; September 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-topical-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313. doi:10.1034/j.1600-0536.2002.4705104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-topical-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30855743">
<a name="30855743"></a>Jansen MHE, Kessels JPHM, Nelemans PJ, et al. Randomized trial of four treatment approaches for actinic keratosis. <i>N Engl J Med</i>. 2019;380(10):935-946. doi:10.1056/NEJMoa1811850<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-topical-drug-information/abstract-text/30855743/pubmed" id="30855743" target="_blank">30855743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-topical-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20691883">
<a name="20691883"></a>Minhas S, Manseck A, Watya S, Hegarty PK. Penile cancer--prevention and premalignant conditions. <i>Urology</i>. 2010;76(2 suppl 1):S24-S35. doi:10.1016/j.urology.2010.04.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-topical-drug-information/abstract-text/20691883/pubmed" id="20691883" target="_blank">20691883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313. doi:10.1016/s0140-6736(95)90963-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-topical-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Smetzer.1">
<a name="Smetzer.1"></a>Smetzer J, Cohen M, eds. Hidden medication loss when using a primary administration set for small-volume intermittent infusions. <i>ISMP Medication Safety Alert! Acute Care Edition</i>. 2020;25(24):1-6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tolak.1">
<a name="Tolak.1"></a>Tolak (fluorouracil 4% cream) [prescribing information]. Sanford, FL: Hill Dermaceuticals Inc; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T. Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219. doi:10.1111/j.1525-139X.2007.00280.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorouracil-topical-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9132 Version 273.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
